Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | DUT | P33316 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 14/20 | 0.31 |
| ▸ | CA2 | P00918 | 14/20 | 0.31 |
| ▸ | CA9 | Q16790 | 13/20 | 0.31 |
| ▸ | CA12 | O43570 | 5/20 | 0.31 |
| ▸ | CA7 | P43166 | 5/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.31 |
| ▸ | CA3 | P07451 | 4/20 | 0.31 |
| ▸ | CA4 | P22748 | 4/20 | 0.31 |
| ▸ | CA6 | P23280 | 4/20 | 0.31 |
| ▸ | CA5A | P35218 | 4/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744584 | 0.94 | KDM4E (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL10943473 | 0.93 | TSHR (0.56) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1143263 | 0.93 | TSHR (0.56) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4235404 | 0.93 | TSHR (0.56) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL10990981 | 0.93 | TSHR (0.56) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL10982965 | 0.92 | KDM4E (0.52) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL10949282 | 0.92 | KDM4E (0.58) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL12013275 | 0.83 | DUT (0.40) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL31171203 | 0.83 | DUT (0.40) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL16898660 | 0.83 | DUT (0.40) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643961-B2 | Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2017-05-09 | — | — | US | disclosed |
| EP-2569308-B1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2016-11-23 | — | — | EP | disclosed |
| US-20160264557-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2016-09-15 | — | — | US | disclosed |
| US-9315463-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2016-04-19 | — | — | US | disclosed |
| US-20130281415-A9 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2013-10-24 | — | — | US | disclosed |
| US-20130053359-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | PRAT QUINONES MARIA (ES) | 2013-02-28 | — | — | US | disclosed |
| EP-2386555-A1 | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities | Almirall, S.A. (ES) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254356-A1 | Wheel Bearing Apparatus Incorporated With A Wheel Speed Detecting Apparatus | NTN CORPORATION (JP) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264557-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | KDM4E 3592/4885USP2 1298/4885ALDH1A1 1707/4885 |
| US-20130281415-A9 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | KDM4E 3728/4885USP2 1259/4885ALDH1A1 1849/4885 |
| US-20130053359-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | KDM4E 3836/4885USP2 1301/4885ALDH1A1 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.